Viewing Study NCT03212404

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:16 PM
Ignite Modification Date: 2026-01-22 @ 4:26 PM
Study NCT ID: NCT03212404
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-02-03
First Post: 2017-07-06
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Sponsor: Checkpoint Therapeutics, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Lung Neoplasms View
None Carcinoma, Non-Small-Cell Lung View
None Carcinoma, Small Cell View
None Malignant Mesothelioma, Advanced View
None Head and Neck Cancer View
None Melanoma View
None Merkel Cell Carcinoma View
None Renal Cell Carcinoma View
None Urothelial Carcinoma View
None Classical Hodgkin Lymphoma View
None Cutaneous Squamous Cell Carcinoma View
None Non Hodgkin Lymphoma View
None Endometrial Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Cancer View
None PD-L1 View
None PDL1 View
None PD-1 View
None PD1 View
None Solid tumors View
None Anti PD-L1 View
None Non-small cell lung cancer, NSCLC View
None CK-301 View
None CSCC View
None Skin cancer View